News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cold Genesys, Inc. Continuing Development of CG0070 Oncolytic Virus With GMCSF Expression


9/7/2012 12:12:39 PM

September 07, 2012 -- Cold Genesys, Inc. has reactivated an IND and is pursuing a special protocol assessment (SPA) with the FDA on a pivotal integrated phase II/III clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who have previously failed BCG. Result of SPA decision will be announced in the week of September 10th 2012.

Those interested in the development of this innovative therapy please contact the company 949.200.7680.


Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES